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Mitochondria are perhaps the most sophisticated and dynamic responsive sensing
systems in eukaryotic cells. The role of mitochondria goes beyond their capacity to create
molecular fuel and includes the generation of reactive oxygen species, the regulation of
calcium, and the activation of cell death. In endothelial cells, mitochondria have a profound
impact on cellular function under both healthy and diseased conditions. In this review, we
summarize the basic functions of mitochondria in endothelial cells and discuss the roles of
mitochondria in endothelial dysfunction and vascular diseases, including atherosclerosis,
diabetic vascular dysfunction, pulmonary artery hypertension, and hypertension. Finally,
the potential therapeutic strategies to improve mitochondrial function in endothelial
cells and vascular diseases are also discussed, with a focus on mitochondrial-targeted
antioxidants and calorie restriction.
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INTRODUCTION
Mitochondria are the remnants of aerobic bacteria that invaded
protoeukaryotic cells a billion years ago. Mitochondria are cell’s
metabolic headquarters, fueling oxidative phosphorylation for
adenosine 5′-triphosphate (ATP) production, and driving reac-
tions to manufacture core metabolites for the biosynthesis of
fats, nucleotides, and proteins. The roles of mitochondria in
eukaryotic cells go beyond their capacity to act as a metabolic
mediator. These cellular organelles regulate various cellular pro-
cesses, including proliferation (Mitra et al., 2009), immune
Abbreviations: EC, endothelial cell; ROS, reactive oxygen species; ATP, adenosine
5′-triphosphate; ER, endoplasmic reticulum; mtDNA, mitochondrial DNA; PGC-
1α, peroxisome proliferation-activated receptor γ co-activator 1α; NRF, nuclear
respiratory factor; TFAM, transcription factor A mitochondrial; TFBM, transcrip-
tion factor B mitochondrial; Ang-II, angiotensin II; ETC, electron transport chain;
mROS, mitochondrial ROS; NADPH, nicotinamide adenine dinucleotide phos-
phate; NOX, NADPH oxidase; mitoKATP, mitochondrial ATP-sensitive potassium
channel; MnSOD, manganese superoxide dismutase; PON, paraoxonase; UCP,
Uncoupling protein; ψm, mitochondrial membrane potential; HIF, hypoxia-
inducible factor; NO, nitric oxide; eNOS, endothelial NO synthase; HUVEC,
human umbilical vein endothelial cells; MCU, mitochondrial Ca2+ uniporter;
MCUR1,mitochondrial calcium uniporter regulator 1; TNFR1, tumor necrosis fac-
tor receptor 1; TNF-α, tumor necrosis factor-α; mtNOS, mitochondrial NOS; PI3K,
phosphoinositide-3 kinase; FoxO, Forkhead box ‘Other’; Bcl-2, B-cell lymphoma
2; BAX, Bcl-2-associated X protein; ox-LDL, oxidative low density lipoprotein;
HDL, high density lipoprotein; AMPK, AMP-activated protein kinase; SVEC,
SV40-transformed murine endothelial cell line; VEGF, vascular endothelial growth
factor; NF-κB, nuclear factor-kappa B; PAH, pulmonary artery hypertension; FHR,
Fawn hooded rat; ADMA, asymmetric dimethylarginine; DDAH, dimethylargi-
nine hydrolases; PAEC, pulmonary arterial endothelial cells; EPC, endothelial
progenitor cells; [Ca2+]m, intramitochondrial Ca2+; [Ca2+]c , cytoplasmic Ca2+;
PARP, poly(ADP-ribose) polymerase; mPTP, mitochondrial permeability transi-
tion pore; CSE, cystathionine-γ-lyase; VCAM-1, vascular cell adhesion molecule-1;
TPP, triphenylphosphonium; Mito-Q, mitoquinone; DOCA, deoxycorticosterone
acetate; UV, uric acid; CR, caloric restriction.
response (Zhou et al., 2011a), apoptotic cell death (Kroemer et al.,
2007), and mediates secondary massager signals to the nucleus
(Al-Mehdi et al., 2012).
The ability to utilize oxygen drives the development and
evolution of the cardiovascular system in multicellular organisms
(Dromparis and Michelakis, 2013). In normal vascular systems,
mitochondria regulate various processes in addition to provid-
ing ATP for the vascular cells. In diseased human vascular tissues,
mitochondria change morphologically and functionally. Mice
lacking mitochondrial proteins typically die at the exact time in
development when the cardiovascular system forms, or are more
sensitive to risk factors for cardiovascular system (Miller et al.,
2010; Shenouda et al., 2011; Dong et al., 2013; Kröller-Schön
et al., 2013). The functions of mitochondria in individual types
of vascular cell have attracted increasing scientific attention.
The normal artery contains three layers. The inner layer, the
tunica intima, is lined by a monolayer of endothelial cells (EC)
that is in contact with blood. The middle layer, or tunica media,
contains smooth muscle cells embedded in a complex extracel-
lular matrix. The adventitia, the outer layer of artery, contains
mast cells, nerve endings and microvessels (Libby et al., 2011).
The direct contact of ECs with the blood flow means that they
are particularly vulnerable to damage molecules in the blood
on one hand, and that they have ideally “guard” roles on the
other hand (i.e., sensing alterations in perfusate constituents
and either responding directly or transmitting reactive signals
to nearby cells, such as smooth vascular cells) (Davidson and
Duchen, 2007). Endothelial dysfunction contributes to the devel-
opment of nearly all vascular diseases. Even though ECs have
low mitochondria content, mitochondrial dynamics acts as a piv-
otal orchestrator of EC homeostasis under normal conditions,
www.frontiersin.org May 2014 | Volume 5 | Article 175 | 1
Tang et al. Endothelial mitochondria in vascular diseases
damage of mitochondrial dynamics participates in endothelial
dysfunction and diverse vascular diseases. In this review, we
summarize advances in understanding the roles of mitochon-
dria in ECs and the mechanisms by which EC mitochondria
participate in certain vascular diseases, including atherosclerosis,
diabetic endothelial dysfunction, pulmonary artery hyperten-
sion (PAH) and hypertension. Finally, we discuss briefly current
available mitochondria targeting approaches for the treatment of
vascular diseases.
MITOCHONDRIA IN ENDOTHELIAL FUNCTION
MITOCHONDRIAL CONTENT, SUBCELLULAR LOCALIZATION,
BIOGENESIS AND DYNAMICS IN ENDOTHELIAL CELLS
In comparison with other cell types with higher energy require-
ments, mitochondria content in ECs is modest. In rat ECs, for
example, mitochondria compose 2–6% of the cell volume as
opposed to 28% in hepatocytes and 32% in cardiac myocytes
(Dromparis and Michelakis, 2013; Kluge et al., 2013). The low
content of mitochondria in ECs may indicate that mitochondria-
dependent oxidative phosphorylation is not that important for
energy supplement in those cells. In fact, ECs obtain a large pro-
portion of their energy from the anaerobic glycolytic metabolism
of glucose. In cultured pig aortic ECs, more than 75% of ATP is
provided by glycolysis (Culic et al., 1997). Additionally, 99% of
glucose is catabolized into lactate in isolated coronary microvas-
cular ECs, whose oxygen consumption is mainly attributable
to the oxidation of endogenous substrates (Spahr et al., 1989;
Mertens et al., 1990). Actually, mitochondria are more likely to
serve primarily as essential signaling organelles in the vascular
endothelium (Quintero et al., 2006).
The cellular distribution of mitochondria is important for its
function and its communication with other cellular organelle
(especially endoplasmic reticulum, ER) and nucleus. For example,
in ECs of arterioles isolated from human myocardium, mito-
chondria are anchored to the cytoskeleton. Those mitochondria
release ROS in response to cell deformation by shear stress (Liu
et al., 2008). In addition, exposure of pulmonary artery ECs
to hypoxia triggers a retrograde mitochondrial movement that
requires microtubules and themicrotubulemotor protein dynein,
resulting in the perinuclear clustering of mitochondria. This sub-
cellular redistribution of mitochondria is accompanied by the
accumulation of ROS in the nucleus, which can be attenuated by
suppressing perinuclear clustering of mitochondria with noco-
dazole to destabilize microtubules (Al-Mehdi et al., 2012). In
addition, mitochondria are an important Ca2+ buffering system
that cooperates with ER to maintain cellular Ca2+ hemostasis.
In this regard, the sublocation and interaction with ER are crit-
ical for the role of mitochondria in Ca2+ buffering (Mironov
et al., 2005). Indeed, distance between the ER and mitochon-
dria is associated with intramitochondrial calcium, mitochon-
drial membrane potential (ψm) and mitochondria-dependent
apoptosis in artery vascular cells from PAH (Sutendra et al.,
2011).
The content of mitochondria, which is important for cellular
function, is critically regulated in cells. Cellular mitochon-
dria content depends upon the balance between mitochon-
drial biogenesis and mitophagy. The biogenesis of mitochondria
is a complex and incompletely understood process involving
replication of mitochondria DNA (mtDNA) and expression of
nuclear andmitochondrial genes. Newmitochondria formation is
regulated by the peroxisome proliferation-activated receptor γ co-
activator 1α (PGC-1α), which activates nuclear respiratory factor
(NRF)-1, NRF-2, transcription factor A mitochondrial (TFAM),
and transcription factor B mitochondrial (TFBM). Mitochondria
are dynamic organelles that constantly fuse and divide (col-
lectively termed mitochondrial dynamics) and can build large,
interconnected intracellular networks. During the lifespan of
mitochondria, damage accumulates followed by mitochondrial
fusion and fission to generate functionally normal and dam-
aged mitochondria. Healthy mitochondria re-enter the cycles of
fusion and function in cells whereas the damaged ones depolar-
ize and undergo mitophagy (Kluge et al., 2013). These concerted
activities control mitochondrial morphology and intracellular
distribution and determine their cell type-specific appearance.
The antagonistic and balanced activities of the fusion and fis-
sion machineries shape the mitochondrial compartment, and the
dynamic behavior of mitochondria allows cells to respond to their
physiological conditions. A shift toward fusion favors the genera-
tion of interconnected mitochondria, whereas a shift toward fis-
sion produces numerous mitochondrial fragments (Westermann,
2010). In recent years, research on mitochondrial fusion and
fission has gained much more attention, as it is important
for our understanding of many biological processes, includ-
ing the maintenance of mitochondrial functions, apoptosis and
aging, in ECs (Detmer and Chan, 2007). Defects in mitochon-
dria biogenesis and dynamics have detrimental consequences on
bioenergetic supply and contribute to the endothelial dysfunc-
tion and the pathogenesis of cardiovascular diseases (Ong et al.,
2010; Shenouda et al., 2011). In addition, the observation that
mitochondria biogenesis is inhibited in aging vascular ECs is
important, particularly because systemic vascular diseases such as
atherosclerosis and hypertension are often diseases of the aging
population (Dromparis and Michelakis, 2013).
MITOCHONDRIAL ROS IN ENDOTHELIAL CELLS
Mitochondria are important source of reactive oxygen species
(ROS) and serve as important ROS buffering systems (Figure 1).
Mitochondria can sense danger signals such as infectious agents
or cholesterol crystals. Mitochondria-derived reactive oxygen
species (mROS) are critical signals for the initiation of cellu-
lar responses to stress and disease risk factors. Altered ψm is
an important factor that triggers excess mROS production in
the setting of risk factors, including aging, hypercholesterolemia,
hyperglycemia, smoking, infections and hypoxia. Although most
electrons flowing down the electron transport chain (ETC) redox
gradient ultimately reach complex V, 1–3% of electrons pre-
maturely react with oxygen, at complexes I and III, to form
superoxide and other types of ROS, collectively known as mROS
(Dromparis and Michelakis, 2013). In addition to complexes I
and III, other sources of mROS have been identified in ECs. One
such example is the nicotinamide adenine dinucleotide phosphate
(NADPH) oxidase 4 (Nox4), which is highly expressed in ECs
and has been localized to mitochondria in other tissues, although
mitochondrial localization in ECs remains elusive. Nox4 is the
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FIGURE 1 | Mitochondria ROS regulation in endothelial cell.
Respiratory chain complexes I–IV generate the proton gradient over the
mitochondrial inner membrane that drives ATP generation by ATP
synthase (complex V). Electrons (e−) from NADH and FADH2 pass
through complex I and complex II, respectively, and then to complex III
via the co-enzyme ubiquinol (CoQ). Cytochrome c transfers electrons
from complex III to complex IV, which reduces O2 to form H2O. Flow of
electrons is accompanied by proton (H+) transfer across the inner
mitochondrial membrane (IMM) at complexes I, III, and IV, creating an
electrochemical gradient, ψm. Protons reenter the mitochondrial matrix
through complex V, which uses the proton-motive force to generate ATP.
UCPs and mitoKATP allow protons to return to the matrix, reducing ROS
formation. Complex I leaks electrons to generate O2 toward the matrix,
whereas complex III generates O2 toward both matrix and
intermembrane space (IMS). p66Shc in the IMS subtracts electrons from
cytochrome c to produce O2. Superoxide is dismutated to H2O2 by
CuZnSOD in IMS and by MnSOD in the matrix. H2O2 is reduced to H2O
by glutathione peroxidase (GPX) using GSH, and the resultant oxidized
glutathione (GSSG) is reduced back to GSH by glutathione reductase.
O2− can interact with NO to form ONOO, which may cooperate with
O2 to uncoupling eNOS and amplify ROS production. PON2,
Paraoxonase 2; NOX4, nicotinamide adenine dinucleotide phosphate
oxidase 4; UCP2, uncoupling protein 2; mitoKATP, mitochondrial
ATP-sensitive potassium channel; OMM, outer mitochondrial membrane.
most highly expressed Nox family member in all cells of the
cardiovascular system and is upregulated by a wide variety of
agonists and cellular stresses. In ECs, Nox4 is sensitive to mechan-
ical forces. Nox4 and its homolog Nox2 are required for basal
ROS production and EC proliferation (Lassègue et al., 2012).
Unlike Nox1, endogenous Nox4 predominantly produces H2O2
rather than O2− (Dikalov et al., 2008). Interestingly, a current
report supports that Nox4 is a protective ROS-generating vascular
NADPH oxidase partly through preventing endothelial dysfunc-
tion during ischemic or inflammatory stress (Schröder et al.,
2012). Another example is the growth factor adaptor protein
p66Shc, which functions in mitochondrial signaling. p66Shc facili-
tates the generation of H2O2 by oxidizing cytochrome c (Giorgio
et al., 2005; Paneni et al., 2012). The next source of mROS
to be introduced is the mitochondrial ATP-sensitive potassium
channel (mitoKATP). Although the function of mitoKATP in
ECs is not well-investigated, current evidence shows that phar-
macological mitoKATP activation protects against ischemic cell
death in cultured ECs and prevents endothelial vasodilator func-
tion in Langendorff-perfused guinea pig hearts subjected to
ischemia-reperfusion. In addition, inhibition of mitoKATP chan-
nels also represses high-glucose-induced endothelial cell apopto-
sis (Beresewicz et al., 2004; Feng and Zuo, 2011; Huang et al.,
2012).
Once excessive mROS is produced, cells simply and rapidly
response to oxidative stress by directly targeting the excessive
mROS. Manganese superoxide dismutase (MnSOD), which is the
predominant dismutase in mitochondria, is rapidly inducible and
buffers the superoxide in themitochondria matrix by dismutating
superoxide to H2O2 (Dromparis and Michelakis, 2013). Other
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superoxide dismutases, such as CuZnSOD, buffer the superox-
ide that escapes into the intermembranous space and cytoplasm
or even extracellularly. The levels of H2O2 are downregulated
by antioxidant enzymes, including catalase and peroxidases.
Catalase is located in cytosolic peroxisomes. Important mito-
chondrial peroxidases include thioredoxin-2, peroxididoxin-3,
and glutaredoxin-2. Glutathione peroxidase-1 is located both in
mitochondria and in the cytoplasm of ECs (Kluge et al., 2013).
In addition to superoxide dismutase, other mitochondria pro-
teins may also participate in the buffering of mROS. Paraoxonase
2 (PON2) is one member of the PON gene family that consists
of three proteins (PON1, PON2, and PON3). PON2 is an intra-
cellular membrane-associated protein that is widely expressed in
vascular cells. PON2 protein is localized to the inner mitochon-
drial membrane, where it is associated with respiratory complex
III. PON2 binds with high affinity to coenzyme Q10, an impor-
tant component of the ETC and reduces the production of mROS
(Devarajan et al., 2011). Our previous review in Antioxidants
and Redox Signaling has systemically discussed the features and
functions of the PON gene family (She et al., 2012). Uncoupling
proteins (UCPs), a family of five mitochondria-localized proteins,
may be another antioxidant defense. UCPs generally tend to limit
mROS production. For instance, UCP1 overexpression in ECs
inhibits mROS production (Nishikawa et al., 2000; Cui et al.,
2006), andUCP2 overexpression in human aortic ECs blocks fatty
acid-induced mROS generation (Lee et al., 2005). UCP2 is the
primary isoform in ECs. UCP2 critically modulates ψm and
mROS production (Duval et al., 2002; Lee et al., 2005). UCP2 pre-
serves endothelial function through increasing nitric oxide (NO)
bioavailability secondary to the inhibition of ROS production in
the endothelium of obese diabetic mice (Tian et al., 2012). UCP2
upregulation also ameliorates hyperglycemia-induced endothelial
dysfunction (Sun et al., 2013a).
At relatively low levels, mROS can be critical signaling
molecules that support normal or compensatory function of the
cell (Sena and Chandel, 2012). This fact means that mROS may
increase even as part of normal signaling in the cell while the
mitochondria themselves remain normal. mROS are now known
to be biologically important in a variety of physiological sys-
tems, including adaptation to hypoxia, regulation of autophagy,
immunity, differentiation, and longevity. For instance, cells utilize
an acute increase in mROS to stabilize hypoxia-inducible factor
(HIF) under hypoxia condition and subsequently restrain ROS
production in chronic hypoxia to avoid cellular damage (Sena
and Chandel, 2012). However, if mROS production is signifi-
cantly increased (due to increased oxygen levels and mitochon-
drial metabolism) and exceeds the buffering capacity of MnSOD,
oxidative damage and cellular dysfunction or death ensues. The
superoxide anion in the matrix is highly reactive and can dam-
age mtDNA, lipids, and proteins. mROS can also damage the
high-iron-sulfur-containing ETC complexes themselves, which
may further exacerbate mROS production and set up a vicious
cycle that contributes to endothelial dysfunction and vascular
diseases. In healthy or the early stage of vascular diseases, the com-
bination of mitochondrial dynamics, mitophagy, and biogenesis
may replace damaged mitochondria or their components and
maintain normal mitochondrial function. Nevertheless, these
quality-control mechanisms may be impaired, which may result
in retention of dysfunctional mitochondria that produce excess
ROS and facilitate vascular diseases. Therefore, mROS are ini-
tially considered toxic molecules. Clinical investigations implicate
that many vascular diseases are accompanied with elevated mROS
levels. The mechanisms underlying mROS in vascular diseases
are multiple and complex. One typical mechanism by which
mROS participates in endothelial dysfunction and subsequent
vascular diseases is by uncoupling the endothelial NO synthase
(eNOS). eNOS facilitates the production of NO, which is an anti-
hypertensive, antithrombotic and anti-atherosclerotic molecule.
In human umbilical vein endothelial cells (HUVEC), the mito-
chondrial arginase II is constitutively expressed, whereas the
cytosolic arginase I is barely detectable. Endothelial NO syn-
thesis depends on the activity of arginase II in mitochondria
and L-arginine carriers in cell membrane (Topal et al., 2006).
O2− reacts with NO to form ONOO−, which together with
ROS production leads to mitochondrial dysfunction, as evi-
denced by increased mROS production, depolarization of ψm,
decreased respiratory control ratio, and reduced low-molecular-
weight thiols content. Reaction with O2− limits NO availability,
resulting in eNOS uncoupling. As a consequence of eNOS uncou-
pling, NO production is reduced and the pre-existing oxidative
stress is enhanced, which contribute significantly to endothe-
lial dysfunction and vascular diseases (Li and Förstermann,
2013).
Noticeably, endothelial mitochondrial oxidative stress can
affect the faith of other cell populations, such as the podocytes
in the kidney (Daehn et al., 2014). Endothelial dysfunction pro-
motes podocyte apoptosis. Inhibition of endothelin-1 receptor
type A (EDNRA) or scavenging of mROS prevents podocyte
loss, albuminuria, glomerulosclerosis, and renal failure (Daehn
et al., 2014). The mechanism underlying podocyte apoptosis after
endothelial dysfunction may also include the decrease in NO
bioavailability, given that loss of eNOS from glomerular EC has
been recently demonstrated to affect podocyte function via acti-
vatin of RhoA in diabetes (Yuen et al., 2012). In addition, in
an eNOS-deficient model, glomerular endothelial cell injury pre-
cedes podocyte apoptosis after adriamycin treatment (Sun et al.,
2013c).
MITOCHONDRIA AND CALCIUM HOMEOSTASIS IN THE ENDOTHELIUM
Like other cells, the functions of ECs largely depend on vari-
ous extents on changes in intracellular Ca2+ concentration. For
instance, receptor-dependent agonists, such as acetylcholine and
serotonin, activate eNOS by increasing cytosolic calcium and
stimulating the binding of calcium/calmodulin (Kluge et al.,
2013). Briefly, calcium activates calcium/calmodulin-dependent
protein kinase II, which plays a role in eNOS gene expression
and phosphorylation state, and regulates actin cytoskeletal ele-
ments that influence EC shape, motility, and barrier function as
previously discussed (Cai et al., 2008).
Although ER is the major storage site for calcium, 25% of
cellular calcium is located to mitochondria. Therefore, mito-
chondria are also considered to be an important calcium buffer-
ing system. Mitochondria modulate Ca2+ signals by taking
up, buffering, and releasing Ca2+ at key locations near Ca2+
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release or influx channels (Figure 2). The mitochondria and ER
networks are in very close proximity; actually, the two organelles
communicate and cooperate to regulate calcium trafficking and
thereby orchestrate key aspects of endothelial function (Kluge
et al., 2013). Calcium moving in and out of mitochondria is
highly regulated. In ECs, H2O2-induced increase in mitochon-
dria calcium may depend partly on the decrease of calcium
extrusion via inhibiting the sodium/calcium exchanger (NCX)
(Jornot et al., 1999). UCP2 and UCP3 are fundamental for
mitochondrial Ca2+ uniporter (MCU) activity in human ECs
(Trenker et al., 2007). Mitochondrial calcium uniporter regula-
tor 1 (MCUR1) is an integral membrane protein required for
MCU-dependent mitochondrial Ca2+ uptake. MCUR1 binds to
MCU and regulates ruthenium-red-sensitive MCU-dependent
Ca2+ uptake (Mallilankaraman et al., 2012). MICU1 faces
the intermembrane space to sense cytoplasmic Ca2+and reg-
ulates the Ca2+ threshold and cooperactivity of mitochon-
drial uniporter (Csordás et al., 2013). Mitochondrial Ca2+
uptake controls intracellular Ca2+ signaling, cell metabolism,
cell survival and other cell-type specific functions by buffer-
ing cytosolic Ca2+ levels and regulating mitochondrial effectors
(Rizzuto et al., 2012). The very negative ψm allows mito-
chondria to sequester positive ions such as Ca2+ from the
cytoplasm. Mitochondrial calcium is an important orchestra-
tor of mitochondrial biogenesis per se and increases expres-
sion of PGC1-α (Szabadkai and Duchen, 2008). Physiological
changes in mitochondrial ([Ca2+]m) and cytosolic ([Ca2+]c) cal-
cium concentrations have important regulatory effects on many
aspects of mitochondrial functions, including mROS produc-
tion, energetics, motility, dynamics, and biogenesis (Davidson
and Duchen, 2007; Widlansky and Gutterman, 2011; Kluge et al.,
2013).
There is increasing evidence that altered mitochondrial cal-
cium contributes to endothelial response to pathological stim-
uli. For example, mitochondrial calcium uptake stimulates NO
production in mitochondria of bovine vascular ECs (Dedkova
et al., 2004). Elevated global endothelial concentration of Ca2+
promotes activation of eNOS, which, in turn, leads to the gen-
eration of NO (Katakam et al., 2013). Pharmacological depolar-
ization of endothelial mitochondria promotes the activation of
eNOS by dual pathway involving elevated [Ca2+] as well as by
phosphoinositide-3 kinase (PI3K)-induced eNOS phosphoryla-
tion. Depolarization of mitochondria in ECs promotes cerebral
artery vasodilation (Katakam et al., 2013). Furthermore, activa-
tion of tumor necrosis factor receptor 1 (TNFR1) ectodomain
shedding by mitochondrial Ca2+ determines the severity of
inflammation in mouse lung microvessels. This compensatory
effect blunts the extent of endothelial activation under proin-
flammatory conditions (Rowlands et al., 2011). Additionally,
the functions of many key mitochondrial enzymes, including
PDH, are very Ca2+-dependent (Dromparis and Michelakis,
2013; Kluge et al., 2013). Calcium activates tricarboxylic acid
cycle enzymes and oxidative phosphorylation, thereby increas-
ing ATP production. In addition to its direct effect on metabolic
enzyme activity, a decrease in Ca2+ influx hyperpolarizes
mitochondria, which leads to mitochondrial and endothelial
dysfunction.
FIGURE 2 | Mitochondria in endothelial cell calcium hemostasis.
Endothelial cells uptake Ca2+ through the membrane capacitative Ca2+
entry channel (CCEC). Generally, endoplasmic reticulum (ER) and
mitochondria uptake Ca2+ through sarco/ER Ca2+-ATPase (SERCA) and
mitochondrial Ca2+ uniporter (MCU), respectively. Inositol
1,4,5-triphosphate (IP3) can activate the release of Ca2+ from ER by binding
to IP3 receptor on the membrane of ER. In contrast, mitochondria release
Ca2+ and at the same time uptake Na+through the Na+/Ca2+ exchanger
(NCX). Risk factors such as hypoxia and hyperglycemia, up-regulate mROS
production, which in turn inhibits the activity of mitochondrial NCX, leading
to elevated level of [Ca2+]m and decreased level of [Ca2+]e. Persistent high
level of [Ca2+]m and low level of [Ca2+]e result in mitochondria damage and
ER stress, as well as subsequent endothelial dysfunction (Red arrow).
MITOCHONDRIAL REGULATION OF ENDOTHELIAL SENESCENCE,
APOPTOSIS, AND MITOPHAGY
Over the last decade, accumulating evidence has suggested a
causative link between mitochondrial dysfunction and major
phenotypes associated with endothelial senescence (Figure 3A).
EC senescence is associated with impaired mitochondrial bio-
genesis, reduced mitochondrial mass and altered expression of
components of the ETC and other mitochondrial components
(Ungvari et al., 2008; Dai et al., 2012). Somatic mtDNAmutations
and respiratory chain dysfunction accompany normal endothelial
senescence. Mitochondrial superoxide production increases with
replicative senescence. Damaged mitochondria produce excessive
superoxide andH2O2, which aremajor determinants of telomere-
dependent senescence at the single-cell level that is responsible for
cell-to-cell variation in replicative lifespan (Passos et al., 2007).
Dysfunction of the ETC critically participates in endothelial
senescence. Deficiency of mitochondrial ETC complex IV plays an
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essential role in senescence-induced mitochondrial dysfunction.
In senescent pulmonary artery ECs, the catalytic activity of com-
plex IV decreases by 84%, and the protein level of this subunit is
also reduced in senescent ECs. The downregulation of complex
IV is mediated by reduced synthesis and enhanced degradation of
the mRNA (Zhang et al., 2002). In addition, in senescent ECs, the
mitochondrial antioxidant MnSOD, which is regulated by FoxO
and SIRT1, is significantly downregulated, resulting in dam-
aged capacity of mROS buffering of mitochondria (Minamino
and Komuro, 2007; Zhou et al., 2011b). In the absence of
UCP2, endothelial growth stimulation provokes mitochondrial
network fragmentation and premature senescence via a mecha-
nism involving superoxide-mediated p53 activation (Shimasaki
et al., 2013). In addition to mROS, the change in mitochondrial
morphology, such as interconnected mitochondria, is observed in
senescent ECs (Jendrach et al., 2005). Mitochondria of senescent
HUVECs show a significant and equal decrease in both fusion
and fission activity, indicating that these processes are sensitive
to aging and could contribute to the accumulation of damaged
mitochondria during aging (Jendrach et al., 2005). Decreased
expression of Drp1 and Fis1, two proteins regulating mitochon-
drial fission, mediates mitochondrial elongation in senescent cells
(Mai et al., 2010). Nox4 serves as an important orchestrator of
ECs senescence. Nox4 appears to maintain an highly intercon-
nected mitochondrial network, which may influence mitochon-
drial fission and/or fusion mechanisms in a manner that could
be a contributing factor in the loss of replicative lifespan seen
in senescence (Koziel et al., 2013). Altered mitochondrial quality
control has been shown to correlate to endothelial dysfunction
in aging. One of such examples is that disordered mitochondrial
dynamics and loss of ψm are observed in cell culture models of
senescence in ECs. Improved mitochondrial fitness, as evidenced
by higher ψm, increased ATP production, and decreased dam-
age to mtDNA, is associated with prolonged lifespan of cultured
ECs (Mai et al., 2012). PGC-1α is the central regulator for mito-
chondrial biogenesis and dynamics. A recent work has identified
PGC-1α as a negative regulator of vascular senescence (Xiong
et al., 2013). Altogether, current evidence implies that dysfunc-
tion of mitochondrial ROS buffering activity and mitochondrial
dynamics play a key role in EC senescence.
Mitochondria are implicated in cell death pathways, including
apoptosis and necrosis, which has been reviewed elsewhere (Wang
and Youle, 2009; Tait and Green, 2010). Mitochondria are central
mediators of apoptosis in ECs (Figure 3B). Intrinsic apoptosis
is initiated by cellular stressors, including hypoxia, ROS, oxi-
dized low density lipoproteins (ox-LDL), and DNA damage. Such
stimuli activates BH3-only proteins, which inhibit antiapoptotic
factors, including B-cell lymphoma 2 (Bcl-2) and allow activa-
tion of Bcl-2-associated X protein (BAX) (Kluge et al., 2013).
Supplementation of ECs with mitochondria-targeted antiox-
idants inhibits peroxide-induced mitochondrial iron uptake,
oxidative damage, and apoptosis (Dhanasekaran et al., 2004). Ox-
LDL induces dysfunction of the ψm, leading to cytochrome
c release into the cytosol, and thereby stimulates apoptosis of
human ECs. Apoptosis suppression by CSA correlates with the
prevention of mitochondrial dysfunction and thus indicates the
importance of mitochondrial destabilization in ox-LDL-induced
apoptosis (Walter et al., 1998). Continuous oxidation of high
density lipoprotein (HDL) under hyperglycemic conditions may
induce endothelial apoptosis through a mitochondrial dysfunc-
tion, following the deterioration of vascular function (Matsunaga
et al., 2001). High glucose increases intracellular ROS and
cell apoptosis through a mechanism involving interregulation
between cytosolic and mROS generation. C-peptide activation of
AMP protein kinase α subunit (AMPKα) inhibits high glucose–
induced ROS generation, mitochondrial fission, ψm collapse,
and EC apoptosis (Bhatt et al., 2013). PGC-1α regulates ROS
generation and apoptosis in ECs by increasing fatty acid oxida-
tion and enhancing ATP/ADP translocate activity (Won et al.,
2010). FOXO3a governs early and late apoptotic endothelial pro-
grams during elevated glucose through mitochondrial and cas-
pase signaling (Hou et al., 2010). Factors regulating the release
of cytochrome c critically participate in mitochondria-dependent
apoptosis of EC. A1, one of Bcl-2 family members, is local-
ized to and functions in mitochondria. A1 is able to repress
mitochondrial depolarization, loss of cytochrome c, cleavage of
caspase 9, BID and poly(ADP-ribose) polymerase. A1 maintains
temporary survival of ECs in response to TNF-α by maintain-
ing mitochondrial viability and function (Duriez et al., 2000).
Apoptosis signal-regulating kinase 1 (ASK1) mediates cytokines
and ROS-induced apoptosis in a mitochondria-dependent path-
way. Overexpression of thioredoxin-2 inhibits ASK1-induced
apoptosis without effects on ASK1-induced JNK activation in EC.
Moreover, specific knockdown of thioredoxin-2 in EC increases
TNF/ASK1-induced cytochrome c release and cell death with-
out increase in JNK activation, Bid cleavage, and Bax translo-
cation (Zhang et al., 2004). Hepatocyte growth factor (HGF),
which is a novel member of the angiogenic growth factors,
can also inhibits cytochrome c release and EC apoptosis by
upregulating the level of Bcl-2 (Nakagami et al., 2002). In addi-
tion to apoptosis, mitochondria are also involved in necrosis.
Mitochondria-mediated necrosis critically participates in cardiac
myocyte dysfunction and cell death. However, whethermitochon-
dria function in EC necrosis remains elusive. A recent report has
showed that mitochondria do not contribute to TNF-α-induced
necrosis in SVEC cells, an established murine endothelial cell
line (Tait et al., 2013). However, it remains to explore whether
mitochondria participate in necrosis in ECs from other tis-
sues or species, or whether pathological stimuli can induce EC
necrosis.
Autophagy is an evolutionally conserved cellular process in
which cells “eat” themselves to fill the energy demand or to
recycle substrates or organelles that are damaged. Mitophagy
refers to the selective autophagy of mitochondria. As mito-
chondrial damage accumulates, networks undergo rearrangement
and fission to yield different populations of daughter mito-
chondria. While the normal daughter mitochondria re-enter the
mitochondria life cycle, the damaged ones undergo mitophagy
to reduce damage such as mROS (Figure 3C). Accumulating
evidence suggests that impaired mitophagy contribute to the
pathogenesis of vascular diseases including diabetes mellitus,
atherosclerosis, and hypertensive heart diseases. Several recent
studies have examined the involvement of mitophagy in ECs
under conditions of oxidative stress and energy deprivation.
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FIGURE 3 | Mitochondria in endothelial cell senescence, apoptosis,
and mitophagy. (A) Aging and other damage signals such as
hyperglycemia inhibit the activation of dynamic proteins, such as
dynamin-related protein-1(Drp1), fission 1(Fis1), and PGC-1α, which leads
to the defects of mitochondria dynamics and endothelial senescence.
When exposed to senescent signals, cellular SIRT1 and FoxO are
downregulated, which results in downregulation of the antioxidant
MnSOD. At the same time, the defected ETC and NOX4 produce more
mROS. Those facts leads to accumulation of mROS, which in turn results
in eNOS uncoupling and p53 activation, and subsequently endothelial cell
senescence. (B) Damage signals lead to a loss of transmembrane
potential (ψm), accumulation of mROS and Ca2+. These effects of
mitochondrial dysfunction contribute to the release of cytochrome c,
which activates Caspase 9-Apaf complex and leads to apoptosis by
activating Caspase 3. Hyperglycemia or hyperlipemia can promotes Bax to
move to the membrane of mitochondria (which can be inhibited by Bcl-2)
to promote the release of cytochrome c. (C) During normal lifespan of
mitochondria and in the settings of increased oxidative stress, damage to
mitochondrial components accumulates. Fission, which is mediated by
Drp1 and Fis1, provides a mechanism to isolate damaged components
for elimination. The damaged mitochondria undergo mitophagy. Mitophagy
involves mitochondrial depolarization, retention phosphatase and tensin
homolog-induced putative kinase protein 1(PINK1) in the mitochondrial
membrane, and recruitment of Parkin, which targets the mitochondria to
autophagosome. Beclin1 and p62 also play a role in targeting cargo to the
autophagosome and are subsequently degraded during active autophagy.
Oxidative damage induced by mitochondria-targeted irradiation
of ECs promotes Parkin translocation to depolarized mitochon-
dria and increases LC3-II level and autophagosome formation
(Mai et al., 2012). When exposed to hemin, ECs undergo
lipid peroxidation, leading to mitochondria depolarization and
mitophagy (Higdon et al., 2012). However, it is also reported
that beclin-1/LC3-II-mediated autophagy is also a mechanism
for ECs to cleat ox-LDL as well. Taken together, autophagy
and mitophagy are important responses of ECs to oxidative
stress.
In summary, mitochondria critically participate in endothelial
cell senescence, apoptosis and mitophagy, and the three aspects
are important for endothelial cell function. However, those three
processes are individually known in EC. How they crosstalk to
regulate endothelial function remains unknown. It is interesting
to explore whether mitochondria could cooperate those processes
in EC.
ENDOTHELIAL MITOCHONDRIA IN VASCULAR DISEASES
Endothelial dysfunction has been linked to a variety of dis-
ease states, including atherosclerosis, diabetes mellitus, coro-
nary artery disease, hypertension, and hypercholesterolemia.
Mitochondria-mediated dysfunction of ECs are critical in those
diseases. Endothelial mitochondria serve as a pivotal sensor of
the local environment and transduce damage signals, which
leads to mitochondria damage, endothelial dysfunction, vascu-
lar remodeling and vascular diseases (Figure 4). Here we focus on
atherosclerosis, diabetic endothelial dysfunction, PAH and hyper-
tension to discuss the role of endothelial mitochondria in vascular
diseases.
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FIGURE 4 | Mitochondria as a sensor of damage signals. Mitochondria
serve as a sensor of environmental damage signals, such as
hyperglycemia, aging, hypoxia, high salt, and smoking. Those risk factors
cause mitochondria damage and subsequent endothelial dysfunction.
Endothelial dysfunction leads to inflammation, oxidative stress and cell
death, which result in vascular remodeling and subsequent vascular
diseases. The “?” means that it is largely unknown how risk factors induce
mitochondria dysfunction.
ATHEROSCLEROSIS
Atherosclerosis is a chronic disease of the arterial wall, which is a
leading cause of death and loss of productive life years worldwide.
Atherosclerosis begins with the recruitment of inflammatory cells
to the intima. Therefore, endothelial layer is the first barrier
against atherosclerosis, and endothelial dysfunction is frequently
involved in atherosclerosis.
Atherosclerosis is associated with a number of metabolic dis-
turbances including diabetes, abnormal lipid metabolism, obe-
sity; and metabolism, implicating mitochondrial component.
Interestingly, the endothelial mitochondria themselves partici-
pate in atherosclerosis. One of the major mechanisms underlying
endothelial mitochondria participate in atherosclerosis is ele-
vated mROS, which leads to endothelial dysfunction or apoptosis,
the earliest event; and inflammation, one of the most domi-
nant features of arthrosclerosis. What is important is that ECs
are more sensitive to reactive species-mediated damage than
smooth muscle cells (Ballinger et al., 2000). mROS is increased
in response to many atherosclerosis inducers, including ox-LDL,
triglycerides, and hyperglycemia. For example, exposure of ECs
to free fatty acids, which upregulate in patients with metabolic
syndrome, increases mROS (Du et al., 2006). Otherwise, hyper-
glycemia changes mitochondrial dynamics and increases mROS
in ECs, while the normalization of blood sugar inhibits the pro-
gression of vascular damage (Nishikawa et al., 2000; Yu et al.,
2006; Shenouda et al., 2011). ROS produced in the vascular
microenvironment causes mitochondrial damage and dysfunc-
tion, which in turn amplifies this effect partly due to reduced
ROS buffering capacity. Mitochondrial protein synthesis is inhib-
ited in a dose-dependent manner by ONOO−, resulting in
decreased cellular ATP levels and mitochondrial redox function
(Ballinger et al., 2000). Reduced synthesis of NO contributes
to the endothelial dysfunction and may be related to limited
availability of L-arginine, the common substrate of constitu-
tive NOS and cytosolic arginase I and mitochondrial arginase
II. Mitochondrial arginase II modulates NO synthesis through
nonfreely exchangeable L-arginine pools in human ECs. Selective
endothelial overexpression of arginase II induces endothelial dys-
function and enhances atherosclerosis in mice (Vaisman et al.,
2012). Atherosclerosis actually happen in old people and mROS
is elevated in aged vascular tissues. Vascular ECs with senescence-
associated phenotypes are present in human atherosclerotic
lesions, and EC senescence induced by telomere shortening may
contribute to atherosclerosis (Minamino et al., 2002).
Another vulnerable target of mROS is mtDNA, owing to
ETC proximity and the relative lack of mtDNA repair mecha-
nisms. Elevated mtDNA damage indwells in human atheroscle-
rotic samples compared with age-matched transplant donors. In
atherosclerosis-prone ApoE−/− mice and in human arterial spec-
imens, the extent of atherosclerosis correlates with mtDNA dam-
age (Ballinger et al., 2002). Since mitochondrial mutations may
lead to production of more ROS, it may initiate a cycle of positive
feedback. Failure of DNA repair generates defects in cell prolifer-
ation, apoptosis, and mitochondrial dysfunction, which in turn
leads to ketosis, hyperlipidemia, and increased fat storage, pro-
moting atherosclerosis and metabolic syndrome. In addition, this
may also implicate the possibility that inherited mtDNA damage
mutations could even initiate vascular damage and increase the
risk of atherosclerosis (Nomiyama et al., 2004; Abu-Amero and
Bosley, 2006; Sobenin et al., 2012a,b, 2013). A recent report has
shown that mtDNA damage can promote atherosclerosis inde-
pendently of ROS through effects on smooth muscle cells and
monocytes and correlates with higher risk plaques in human (Yu
et al., 2013). However, the relationship between atherosclerosis
and mitochondrial mutations in ECs remains elusive.
Factors that modulate endothelial mROS production are
evidenced to participate in atherosclerosis. One of such exam-
ples is the adaptor protein, p66Shc. The fact that the expres-
sion of p66Shc may be relevant in cardiovascular function is
evident from the observations that p66Shc knockout mice are
protected against ROS-dependent, age-related endothelial dys-
function (Francia et al., 2004), hyperglycemia-induced endothe-
lial dysfunction (Zhou et al., 2011b), as well as high-fat-induced
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atherosclerosis (Napoli et al., 2003; Martin-Padura et al., 2008).
The function of p66Shc is regulated by SIRT1 at the chromatin
level (Zhou et al., 2011b). Previous work in our laboratory
showed that endothelial-specific SIRT1 transgenic mice exhibit
smaller atherosclerotic lesions, which may be partly attributed
to the reduced local ROS in the lesions (Zhang et al., 2008).
This effect may be at least partly contributed by the effects of
SIRT1 on endothelial mitochondria, because resveratrol, a nature
activator of SIRT1, can attenuates mitochondrial oxidative stress
in coronary arterial ECs (Ungvari et al., 2009). In addition,
endothelial-specific expression of mitochondrial thioredoxin-2
improves endothelial cell function and reduces atherosclerotic
lesions. Thioredoxin-2 TG mice have increased total antioxi-
dants, reduced oxidative stress, and increased NO levels in serum
compared with their control littermates. Consistently, aortas
from thioredoxin-2 TG mice show reduced vasoconstriction and
enhanced vasodilation (Zhang et al., 2007).
Current research focuses mainly on the oxidation-reduction
process mediated by mitochondria. Other roles of mitochon-
dria in mediating endothelial function in atherosclerosis remain
elusive. Our current understanding indicates that atherosclerosis
is a metabolic disease and endothelial cell mentalism is impor-
tant for their function in the artery. However, it is unknown
whether mitochondria-mediated alteration of metabolism in EC
participates directly in atherosclerosis.
DIABETIC VASCULAR DYSFUNCTION
Diabetes mellitus is associated with an increased risk of cardiovas-
cular disease even in the presence of intensive glycemic control.
Vascular ECs are an important target of hyperglycaemic dam-
age. Mitochondrial dysfunction plays a central role in endothelial
dysfunction in type II diabetes mellitus (Kizhakekuttu et al.,
2012). In type II diabetes patients, mitochondrial function is
impaired, which is evident from lower mitochondrial O2 con-
sumption, ψm, polymorphonuclear cell rolling velocity, and
GSH/GSSG ratio, and higher mROS production and rolling flux
(Hernandez-Mijares et al., 2013).
Hyperglycemia-induced increase in the production of ROS
by the mitochondrial ETC in EC has been implicated in
glucose-mediated vascular damage (Nishikawa et al., 2000;
Brownlee, 2001; Du et al., 2003). Activation of AMPK reduces
hyperglycemia-induced mROS production and promotes mito-
chondrial biogenesis in HUVECs (Kukidome et al., 2006). In
both mature ECs and EPCs, AMPK activation by its agonists
suppresses high-glucose-induced ROS generation by promot-
ing mitochondrial biogenesis (Kukidome et al., 2006), inhibiting
NADPH oxidase activity (Ceolotto et al., 2007), and inducing
the expression of both mitochondrial UCP2 (Xie et al., 2008),
and MnSOD (Wang et al., 2011b). Endothelium-selective acti-
vation of AMPK prevents diabetes mellitus-induced impairment
in vascular function and reendothelialization (Li et al., 2012).
In this regard, AMPK activator such as metformin could serve
as candidate drug to improve mitochondria and subsequent
endothelial function. Interestingly, a recent report has showed
that mROS enhances AMPK activation in the endothelium of
patients with coronary artery disease and diabetes (Mackenzie
et al., 2013). This finding may implicate that high glucose induces
endothelial dysfunction by upregulating mROS, which in turn
leads to the activation of AMPK. This feedback pathway may be a
conserved pattern for the body to protect itself. Hyperglycemia
inhibits thioredoxin ROS-scavenging function through induc-
tion of thioredoxin-interacting protein (Txnip), which interacts
with thioredoxin and serves as an endogenous inhibitor (Schulze
et al., 2004; Li et al., 2009). Overexpression of Txnip increases
oxidative stress, while Txnip gene silencing restores thioredoxin
activity in hyperglycemia (Schulze et al., 2004). In addition, Txnip
induces inflammation through chromatin modification in reti-
nal capillary EC under diabetic conditions (Perrone et al., 2009).
Importantly, diabetic animals exhibit increased vascular expres-
sion of Txnip and reduced thioredoxin activity, which normalizes
with insulin treatment (Schulze et al., 2004).
Mitochondria also contribute to hyperglycemia-induced EC
apoptosis. In addition to mROS overproduction, other pathways
have essential roles in this process. Mitochondria depolariza-
tion has been implicated in hyperglycemia-induced apoptosis of
human aortic ECs. Apoptosis in human aortic ECs induced by
hyperglycemia involves mitochondrial depolarization and mROS
overproduction, which is prevented by the antioxidant N-acetyl-
L-cysteine (Recchioni et al., 2002). ROCK1 is a potent regulator
of mitochondrial dynamics in diabetic nephropathy and Drp1
is a direct substrate for ROCK1. In hyperglycemic conditions,
ROCK1 phosphorylates Drp1 and leads to mitochondrial fis-
sion, mROS production and subsequent release of cytochrome
c (Wang et al., 2012). In retinal ECs, high glucose downregu-
lates mitochondrial connexin 43, which leads to mitochondria
shape change and cytochrome c release (Trudeau et al., 2012).
Hyperglycemia-induced mitochondrial fragmentation with con-
comitant increase in ψm heterogeneity, reduced oxygen con-
sumption, and cytochrome c release may underlie apoptosis of
retinal EC as seen in diabetic retinopathy (Trudeau et al., 2010).
The mitochondrial permeability transition pore (mPTP) is an
oxidative stress–sensitive channel involved in cell death. Elevated
glucose concentration leads to an oxidative stress that favors
mPTP opening and subsequent cell death in several endothelial
cell types andmetformin prevents this mPTP opening–related cell
death (Detaille et al., 2005).
For a long time, it was unknown why vascular damage still
occurs in diabetes patients even in the presence of intensive
glycemic control. Hyperglycemic memory may explain why
intensive glucose control has failed to improve cardiovascular
outcomes in patients with diabetes. Indeed, hyperglycemia
promotes vascular dysfunction even after glucose normalization.
Accumulating observations support the concept that ROS-driven
hyperglycemic stress is remembered in the vasculature. The
mitochondrial adaptor protein p66Shc critically participates in
the hyperglycemic memory in vascular ECs. In human aortic
ECs exposed to high glucose and aortas of diabetic mice, acti-
vation of p66Shc by protein kinase C β II (PKCβII) persist after
returning to normoglycemia. Persistent p66Shc upregulation
and mitochondrial translocation are associated with continued
ROS production, reduced NO bioavailability, and apoptosis.
In vitro and in vivo gene silencing of p66Shc, performed at the
time of glucose normalization, blunts ROS production, restores
endothelium-dependent vasorelaxation, and attenuates apoptosis
www.frontiersin.org May 2014 | Volume 5 | Article 175 | 9
Tang et al. Endothelial mitochondria in vascular diseases
by limiting cytochrome c release, caspase 3 activity, and cleavage
of PARP (Paneni et al., 2012). Our previous study showed that
SIRT1 inhibited high-glucose-induced p66Shc upregulation in
HUVECs. Moreover, compared with streptozotocin-induced
wild-type diabetic mice, endothelium-specific SIRT1 trans-
genic diabetic mice had decreased p66Shc expression, improved
endothelial function, and reduced accumulation of nitrotyrosine
and 8-OHdG (Zhou et al., 2011b). This finding implicates
that SIRT1 may be an important regulator of hyperglycemic
memory. The relationship among SIRT1, p66Shc, oxidative stress,
damage memory and endothelial senescence has been discussed
previously (Chen et al., 2013).
In conclusion, mitochondria are essential for hyperglycemia-
induced endothelial dysfunction. Mitochondria function in this
process through at least three pathways: mROS production,
apoptosis and damage memory. Hyperglycemia upregulates the
production of mROS and inhibits activity of the endothelial
ROS buffering system, which leads to damage of mtDNA and
other mitochondrial components that are important for normal
endothelial function. In addition, the balance between antiapop-
totic and proapoptotic pathways is broken. Therefore, current
research has deeply investigated the participation of mitochon-
dria in hyperglycemia-induced endothelial dysfunction. However,
how mitochondria-mediated endothelial dysfunction contributes
to secondary vascular diseases, such as atherosclerosis, remains
unclear.
PULMONARY ARTERY HYPERTENSION
PAH is an ideal vascular disease to discuss for the reason that it
reflects all the function of mitochondria so far. PAH is caused
by excessive proliferation of vascular cells such as smooth mus-
cle cells and ECs that eventually obliterate the pulmonary arterial
lumen, and lead to right ventricular failure and premature death.
The cause of the vascular remodeling in PAH remains elusive
and the prognosis of PAH is still poor. Abnormal mitochondria
in PAH pulmonary arteries suppress mitochondria-dependent
apoptosis and contribute to vascular remodeling. Although many
investigations in this field focus on smooth muscle cells, the role
of EC attracts increasing attentions. Similar to atherosclerosis,
EC dysfunction and apoptosis appears to be an early event in
PAH. However, later stages are characterized by the presence of
hyperproliferative and apoptosis-resistant ECs and smooth mus-
cle cells. These cells exhibit a metabolic profile strikingly similar
to that of cancer cells (Dromparis and Michelakis, 2013).
In PAH, mitochondrial signaling regulates both the acute and
the chronic response of the pulmonary circulation to hypoxia,
and defect in mitochondrial glucose oxidation contributes to
the apoptosis-resistance and proliferative diathesis. The switch
provides several advantages to EC, including: (i) diversion of
pyruvate into anabolic pathways; (ii) suppression of apopto-
sis by hyperpolarized ψm; (iii) inhibition of Kv channels due
to decreased mROS, increasing cytosolic Ca2+, which in turn
activates hyperproliferative transcription factor nuclear factor of
activated T cells (NFAT), whose activation causes downregula-
tion of Kv channels and upregulation of glycolytic enzymes; and
(iv) activation of the HIF1, which increases pyruvate dehydro-
genase kinase (PDK) expression, thus sustaining mitochondrial
suppression in another reinforcing feedback loop (Dromparis and
Michelakis, 2013). For instance, lactate dehydrogenase A converts
pyruvate to lactate necessary to sustain rapid flux through
glycolysis. Pulmonary microvascular endothelial cells (PMVEC)
utilize aerobic glycolysis to sustain their rapid growth rates, which
is dependent on lactate dehydrogenase A (Parra-Bonilla et al.,
2010).
The primary role of mitochondria in vascular ECs may be not
to produce ATP but, under the control of NO, to act as signaling
organelles using either oxygen of oxygen-derived species as signal-
ing molecules. At a low oxygen concentration, endogenous NO
plays a key role in preventing the accumulation and stability of
HIF1α. At higher oxygen concentrations, NO facilitates the pro-
duction of mROS (Quintero et al., 2006). Oxygen consumption of
PAH cells is decreased, especially in state 3 respiration with sub-
strates glutamate-malate or succinate, and this decrease parallels
reduction in complex IV activity and PAH cellular NO synthesis.
PAH pulmonary artery ECs have decreased mitochondrial dehy-
drogenase activity and lowered mitochondrial numbers per cell
and mtDNA content, all of which increase after exposure to NO
donors (Xu et al., 2007). Alterations of NO and MnSOD con-
tribute to pathological HIF-1α expression and account for lower
numbers of mitochondria in PAH-EC (Fijalkowska et al., 2010).
Asymmetric dimethylarginine (ADMA) is an endogenous com-
petitive inhibitor of NOS. Elevated ADMA levels are observed
in numbers of conditions affecting the cardiovascular system.
Recently, ADMA is shown to increase in Shunt lambs secondary
to a decrease in dimethylarginine hydrolases (DDAH) activity and
that ADMA increases the nitration of mitochondrial proteins in
cultured lamb pulmonary arterial endothelial cells (PAEC) (Sud
et al., 2008; Sun et al., 2011). Treatment of Shunt lambs with
L-arginine prevents the ADMA-mediated mitochondrial redis-
tribution of eNOS, the nitration-mediated inhibition of CrAT,
and maintains carnitine homeostasis. In return, ATP levels and
eNOS/heat shock protein 90 interactions are preserved, which
decreases NOS uncoupling and enhances NO generation (Sun
et al., 2013b).
Taken together, endothelial mitochondria participate in PAH
through two main ways: aerobic glycolysis to provide substrates
for cell growth and to improve the ROS system to promote cell
proliferation and inhibit cell apoptosis. However, current studies
focus mainly on the role of smooth muscle cells in PAH; fur-
ther experimental investigations are needed to estimate the role
of mitochondrial regulation of endothelial dysfunction in this
disease.
HYPERTENSION
Hypertension is a condition associated with oxidative stress,
endothelial dysfunction, and increased vascular resistance,
representing probably both a cause and a consequence of ele-
vated levels of ROS and nitrogen species. Mitochondrial dys-
function, preceding endothelial dysfunction, might favor the
development of hypertension. Genetic studies have implicated
the role of mitochondrial in hypertension. Gly482Ser polymor-
phisms in PGC-1α, a factor controlling mitochondria biogene-
sis, are associated with blood pressure and hypertension among
Austrian men and white subjects (Oberkofler et al., 2003; Cheurfa
et al., 2004; Andersen et al., 2005). A study carried out in
Korean population correlates age-dependent polymorphisms in
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the mitochondria-shaping gene, OPA1, with blood pressure and
hypertension (Jin et al., 2011). Mitochondrial dysfunction caused
by mitochondrial tRNAlle 4263A>G mutation is involved in
essential hypertension (Wang et al., 2011a).
In situations of metabolic perturbation, increased mROS
generation might trigger EC dysfunction, possibly contribut-
ing to the development of hypertension (Puddu et al., 2008).
Thioredoxin 2, a mitochondria specific antioxidant enzyme, can
attenuate Ang-II-induced hypertension (Widder et al., 2009).
Nox2 contributes to mROS production and EC dysfunction
(Nazarewicz et al., 2013). Nox2 depletion in gp91phox knockout
mice inhibits Ang-II-induced cellular and mROS and attenuates
hypertension (Dikalov et al., 2014). Ang-II induces endothelial
mROS production. Overexpression the mitochondrial MnSOD
elevates both basal and Ang-II-stimulated cellular superox-
ide. Furthermore, transgenic mice overexpressing mitochondria
MnSOD attenuates Ang-II induced hypertension (Dikalova et al.,
2010).
Compared with the studies on atherosclerosis, diabetes and
PAH, much less work has been carried out in hypertension, and
those studies mainly focus on the mROS. It is interesting to inves-
tigate other roles of mitochondria in hypertension. For instance,
eNOS is important for endothelial cell function and eNOS uncou-
pling is observed in hypertension of animal models. Whether
mitochondria participate in this process remains unknown.
MITOCHONDRIA TARGETING INTERVENTION
Risk factors induce mitochondrial dysfunction in the EC, which
contributes to the pathogenesis of various vascular diseases.
Those findings prompt the speculation that interventions that
restore mitochondrial function or “re-educate” mitochondria
may be protective in endothelial dysfunction and related vascu-
lar diseases. Here we discuss mitochondria-directed antioxidants
and interventions that improve mitochondria functions.
MITOCHONDRIA-DIRECTED ANTIOXIDANTS
Mitochondria-derived ROS are important for signaling and EC
dysfunction in vascular system, a strategy reguiding ROS to phys-
iological levels likely will be effective. Although clinical trials of
non-targeted antioxidants (such as vitamins A or E, selenium,
or β-carotene) have not shown to function well, mitochondria-
targeting antioxidants may offer improved efficacy. Because mito-
chondria are the most negatively charged organelles. Positively
charged molecules have a preferential up-take in mitochondria
and achieve mitochondrial concentrations as much as 1000-fold
higher than in the cytoplasm. Therefore, one strategy to target
mROS is to link antioxidant compounds with a lipophilic cation,
such as triphenylphosphonium (TPP) (Dai et al., 2012; Smith
et al., 2012). Several such agents have been designed.
Mitoquinone (mitoQ) is reduced to ubiquinol within the
mitochondrial matrix. Investigators enhance mitochondrial
function selectively by attaching mitoQ to TPP via a long
lipophilic alkyl chain (James et al., 2005). Administration of
the mitochondria-targeted antioxidant mitoQ protects against
the development of hypertension, improves endothelial function,
and reduces cardiac hypertrophy in young stroke-prone spon-
taneously hypertensive rats (Graham et al., 2009). Furthermore,
mitoQ has been shown to prevent diabetic nephropathy and car-
diac dysfunction (Chacko et al., 2010; Vergeade et al., 2010).
MitoQ has been used to target mROS in many nonvascular
diseases in animals and even in early-phase clinical trials (Smith
and Murphy, 2010). A recent work demonstrated that mitoQ
treatment reduced the macrophage content and cell proliferation
within plaques of atherosclerosis (Mercer et al., 2012).
A similar strategy has been performed to deliver α-tocopherol
or the mitochondria-targeting TEMPOL (mitoTEMPO) to mito-
chondria. Treatment with mitoTEMPO attenuates hypertension
when given at the onset of Ang-II infusion and decreases blood
pressure by 30mm Hg following establishment of both Ang-II-
induced and DOCA salt hypertension, whereas a similar dose
of non-targeted TEMPO was not effective. In vivo, mitoTEMPO
decreases vascular O2−, increases vascular NO production and
improves endothelial-dependent relaxation. Interestingly, trans-
genic mice overexpressing MnSOD show attenuated Ang-II-
induced hypertension and vascular oxidative stress similar tomice
treated withmitoTEMPO (Dikalova et al., 2010). Anothermimet-
ics of MnSOD is metalloporphyrin Mn (III) tetrakis (4-benzoic
acid) porphyrin (MnTBAP). Administration ofMnTBAP reverses
the hyperproliferative PAH phenotype in vitro and in vivo (Archer
et al., 2010).
Some antioxidants, which may be not designed to target mito-
chondria, are shown to improve mitochondria function signifi-
cantly. One of such examples is the vitamin D, which has been
known to be important in many cellular functions of several
tissues and organs other than bone. Vitamin D receptors have
been found in all the major cardiovascular cell types including
cardiomyocytes, arterial wall cells, and immune cells (Norman
and Powell, 2014). Vitamin D alone or in combination with
ZK191784 is able to prevent the loss of mitochondrial potential
and the consequent cytochrome c release and caspase activa-
tion in HUVEC undergoing oxidative stress (Uberti et al., 2013).
Moreover, vitamin D is a regulator of eNOS and arterial stiff-
ness in mice (Andrukhova et al., 2013). Vitamin D insufficiency
is associated with depletion of circulating endothelial progenitor
cells and endothelial dysfunction in patients with type 2 diabetes
(Yiu et al., 2011). A single large dose of oral vitamin D improves
endothelial function in patients with type 2 diabetes (Sugden
et al., 2008). Nevertheless, the role of vitamin D supplementa-
tion in the management of cardiovascular disease remains to be
established.
CALORIC RESTRICTION AND MIMETICS
Caloric restriction (CR) is a dietary regimen that offers ben-
efits by improving mitochondria function and quantity con-
trol. CR decreases mROS at complex I and lowers oxidative
damage to mtDNA in the rat heart (Gredilla et al., 2001). In
animal models and human patients, CR increases mitochon-
drial biogenesis and bioenergetic efficiency (Nisoli et al., 2005;
López-Lluch et al., 2006; Civitarese et al., 2007). CR was first
reported to lower blood pressure in the spontaneously hyper-
tensive rat 35 years ago (Young et al., 1978). A recent work
has showed that CR ameliorates Ang-II-induced cardiomyocytes
hypertrophy, vascular inflammation partly through reprogram-
ming mitochondria proteomic profile in rats (Finckenberg et al.,
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2012). In addition, CR reduces atherosclerosis and oxidative stress
in the aorta of ApoE−/− mice (Guo et al., 2002). Importantly,
CR can significantly reduce the onset of cardiovascular diseases
in monkeys (Colman et al., 2009). In human, long-term CR
is highly effective in reducing the risk for atherosclerosis and
hypertension (Fontana et al., 2004). CR alone and with exer-
cise reduces CVD risk in healthy non-obese individuals (Lefevre
et al., 2009). CR is shown to regulate several pivotal orches-
trators in metabolic, including AMPK, SIRT1, and mammal
target of rapamycin (mTOR) as well as insulin-like growth fac-
tors (Fontana et al., 2010). Activators/inhibitors of those proteins
are demonstrated to be CR mimics and mediate mitochondria
function.
Resveratrol is an activator of AMPK and SIRT1. Treatment
of rats with resveratrol increases expression of eNOS, decreases
oxidative stress, and improves endothelial function in small
pulmonary arteries. Resveratrol prevents monocrotaline-induced
PAH in rats (Csiszar et al., 2009). In addition, resveratrol sup-
presses atherosclerosis in hypercholesterolemic rabbits without
affecting plasma lipid levels (Wang et al., 2005). Metformin,
which activates AMPK, has been shown to inhibit mPTP open-
ing and endothelial cell apoptosis and to prevent endothelial
dysfunction in experimental models (Schulz et al., 2008) and
to stimulate microvascular repair in acute lung injury (Jian
et al., 2013). The thiazolidinediones, including pioglitazone,
have been reported to activate PGC1-α, a downstream factor of
AMPK and SIRT1, and enhance mitochondrial biogenesis in ECs
(Fujisawa et al., 2009). Rapamycin, the inhibitor of mTOR, is
evidenced to attenuate atherosclerosis (Waksman et al., 2003),
hypertension and PAH (Morales et al., 2001; Nishimura et al.,
2001).
Taken together, accumulating evidence demonstrates that
mitochondria-targeting antioxidants, CR and its mimetics can
reduce vascular diseases. However, what we should notice here
is that although those interventions can improve the function of
EC, further evidence will be requested to verify the essential roles
of endothelial mitochondria in those processes, although genetic
approaches with endothelial specific transgene or knockout of
mitochondria genes have provided strong evidence that endothe-
lial mitochondria is involved in vascular diseases. Therefore,
endothelial mitochondria may act as a promising therapeutic
target to improve endothelial function and to prevent against
vascular diseases.
CONCLUDING REMARKS
Mitochondria content in EC is relatively low in comparison with
those with high-energy demand. EC obtain a large proportion
of energy from the anaerobic glycolytic metabolism of glucose.
Those facts implicate themitochondria in EC are unlikely to act as
an energy factory but, sense the local environment the EC face and
orchestrate the cellular hemostasis and function. Persistent envi-
ronmental risk signals can damage mitochondria, which in turn
produce excessive ROS and accelerate e EC senescence, death and
dysfunction. EC serve as the first barrier of the vascular system,
the dysfunction of endothelial cell is considered to be the patho-
logical basis of various vascular diseases including atherosclerosis,
diabetic vascular dysfunction, PAH and hypertension. Rescuing
mitochondrial function, or “re-educating” the damaged mito-
chondria, has been demonstrated as potential interventions to
improve vascular conditions both in animal models and in
human patients.
However, several interesting issues are up in the air in this
field. The first issue is mitochondria-nucleus communication.
Accumulating evidence have implicated that mitochondria can
send signals to the nucleus, regulating the events in the nucleus.
More importantly, it is interesting to see whether mitochondria
signal influences epigenetic remarks in the nucleus. Acetylation
and methylation of histone tails are dynamics processes reg-
ulated by histone de/acetyltransferases, methyltransferases, or
demethylases. Co-factors, including flavin adenine dinucleotide
(FAD), acetyl-CoA, and α ketoglutarate (α-KG), are associated
with the processes of active de/methylation or de/acetylation
(Minocherhomji et al., 2012). Both FAD and α-KG are known
to be synthesized in mammalian mitochondria. In this regard,
mitochondria are critically important for epigenetic modification
in the nucleus. Altered levels of these co-factors due to mito-
chondrial impairment/dysfunction could have significant effects
on regulation of the nuclear genome, and subsequent endothelial
function. In addition, depletion of mtDNA results in significant
changes in methylation pattern of a number of genes (Smiraglia
et al., 2008). Vascular EC undergo senescence, apoptosis and
mitophagy in disease conditions. All those processes are regulated
at least in part by mitochondria. Therefore, the second question is
whether mitochondria serve as pivotal modulators of those pro-
cesses just as orchestrating a shadow play. Finally, with regard
to mitochondria-targeted approaches, current studies are focus-
ing on the antioxidants. It remains largely unknown the roles of
dysregulated metabolites of the mitochondria in mitochondria
damage and endothelial cell dysfunction. If they are important,
they may serve as potential targets to “re-educate” mitochondria
in EC, and subsequently serve as candidate targets for vascular
diseases therapy.
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